Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new ...

Chinese biotech Innovent Biologics (OTCPK:IVBIY) (OTCPK:IVBXF) has entered into a collaboration and licensing agreement with ...

Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...

Innovent Biologics and Roche have entered a partnership and exclusive licence agreement to accelerate the development of a ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

Innovent Biologics Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines, has entered a ...

Analyst Jill Wu of CMB International Securities maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), boosting the price ...

[ET Net News Agency, 8 January 2025] A direct manual trade of 1.67 million shares of INNOVENT BIO (01801) was registered at 1:00p.m. The deal amounted to HK$56.6m, or at HK$33.8 per share, 3.8% lower ...

Innovent Biologics (HK:1801) has released an update.Don't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall Street ...

SAN FRANCISCO and SUZHOU, China, Jan. 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...